Sunshine Biopharma, Inc. (SBFM)
- Previous Close
0.9300 - Open
0.8830 - Bid --
- Ask 2.0000 x 3200
- Day's Range
0.7630 - 0.8900 - 52 Week Range
0.7500 - 140.0000 - Volume
13,985,379 - Avg. Volume
1,149,301 - Market Cap (intraday)
802,981 - Beta (5Y Monthly) -1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-19.0000 - Earnings Date May 9, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
300.00
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.
sunshinebiopharma.com44
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SBFM
Performance Overview: SBFM
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SBFM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBFM
Valuation Measures
Market Cap
802.98k
Enterprise Value
-14.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.01
Price/Book (mrq)
0.04
Enterprise Value/Revenue
-0.62
Enterprise Value/EBITDA
3.88
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.70%
Return on Assets (ttm)
-10.57%
Return on Equity (ttm)
-21.04%
Revenue (ttm)
24.09M
Net Income Avi to Common (ttm)
-4.51M
Diluted EPS (ttm)
-19.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
16.29M
Total Debt/Equity (mrq)
3.10%
Levered Free Cash Flow (ttm)
-8.2M